Dashboard
Manage Tickers

IMRX Immuneering Corp

Nasdaq immuneering.com


$ 5.94 $ -0.15 (-2.46 %)    

Thursday, 16-Oct-2025 12:07:34 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 603.22 $ -1.93 (-0.32 %)
DIA $ 462.06 $ -1.32 (-0.28 %)
SPY $ 664.39 $ -2.50 (-0.37 %)
TLT $ 90.87 $ 0.36 (0.4 %)
GLD $ 393.47 $ 2.33 (0.6 %)
$ 6.16
$ 6.22
$ 5.93 x 1,000
$ 5.96 x 200
$ 5.93 - $ 6.25
$ 1.10 - $ 10.08
1,621,633
na
223.72M
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 09-09-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-immuneering-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
09/30/2025 11:43:59

HC Wainwright & Co. analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $11 price target.

immuneering-to-host-call-on-september-29-2025-at-830-am-et-to-discuss-updated-survival-and-safety-data-for-atebimetinib--mgnp-in-first-line-pancreatic-cancer
Immuneering To Host Call On September 29, ...
09/26/2025 20:01:59

Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today annou...

chardan-capital-maintains-buy-on-immuneering-raises-price-target-to-20
Chardan Capital Maintains Buy on Immuneeri...
09/26/2025 11:36:16

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ: IMRX) with a Buy and raises the price target from $13...

oppenheimer-maintains-outperform-on-immuneering-raises-price-target-to-30
Oppenheimer Maintains Outperform on Immune...
09/25/2025 13:57:47

Oppenheimer analyst Jay Olson maintains Immuneering (NASDAQ: IMRX) with a Outperform and raises the price target from $21 to...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/25/2025 12:08:49

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket
Why PepGen Shares Are Trading Higher By 11...
09/25/2025 10:11:08

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

Core News & Articles
Immuneering Prices $175M Underwritten Publ...
09/25/2025 06:17:13

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 21:06:04

Core News & Articles
Immuneering Announces Public Offering And ...
09/24/2025 20:11:35

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announ...

immuneering-announces--updated-survival-and-safety-data-from-its-ongoing-phase-2a-trial-of-atebimetinib-in-combination-with-modified-gemcitabinenab-paclitaxel-in-first-line-pancreatic-cancer-patients-with-9-months-median-follow-up--86-overall-survival-observed-at-9-months-co-expects-regulatory-feedback-on-pivotal-trial-plans-in-q4-2025-and-subject-to-that-feedback-expects-to-initiate-pivotal-trial-by-the-end-of-2025-and-begin-dosing-patients-by-mid-2026
Immuneering Announces Updated Survival An...
09/24/2025 20:04:41

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused o...

immuneering-names-thomas-schall-chairman-of-the-board-replaces-ben-zeskind-in-leadership-transition
Immuneering Names Thomas Schall Chairman O...
09/16/2025 11:12:13

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announ...

needham-maintains-buy-on-immuneering-raises-price-target-to-11
Needham Maintains Buy on Immuneering, Rais...
09/15/2025 10:48:21

Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $8 to $11.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 17:07:06

biotech-firm-immuneering-plans-key-cancer-data-presentations-at-upcoming-boston-summits
Biotech Firm Immuneering Plans Key Cancer ...
09/10/2025 11:12:27

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared...

needham-reiterates-buy-on-immuneering-maintains-8-price-target
Needham Reiterates Buy on Immuneering, Mai...
08/26/2025 10:25:30

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $8 price target.

Core News & Articles
Immuneering To Test Atebimetinib With Eli ...
08/25/2025 12:12:58

- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-sm...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/21/2025 17:05:56

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/21/2025 12:08:08

immuneering-announces-private-placement-with-gross-proceeds-up-to-25m
Immuneering Announces Private Placement Wi...
08/21/2025 12:02:29

chardan-capital-maintains-buy-on-immuneering-maintains-13-price-target
Chardan Capital Maintains Buy on Immuneeri...
08/14/2025 20:36:16

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $13 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION